ACCELERATING THE DRYING RATE OF SOFTGEL CAPSULES
The instant invention provides a process for reducing the drying time of softgel capsules by incorporating drying accelerators based on organic sulfonic acids and salts thereof into the formulations used to make the capsules.
1 . A softgel capsule having incorporated in the shell an amount of an organic sulfonate salt which is effective to accelerate the drying rate of said capsule but not effective to provide a pharmacological effect.
2 . The softgel capsule of claim 1 , wherein said organic sulfonate salt is an aromatic sulfonate salt.
3 . The softgel capsule of claim 1 , wherein said organic sulfonate salt is an aliphatic sulfonate salt.
4 . The softgel capsule of claim 2 , wherein said aromatic sulfonate salt is selected from the group consisting of unsubstituted and substituted benzene sulfonates and unsubstituted and substituted naphthalene sulfonates.
5 . The softgel capsule of claim 4 , wherein said salts are selected from the group of alkaline metal salts and alkaline earth salts.
6 . The softgel capsule of claim 3 , wherein said aliphatic sulfonate salt is derived from an ester of an aliphatic dibasic acid having the formula
in which R is an aliphatic carbon chain containing at least one sulphonic group, but free from other substituents, and X is an alcohol or phenol radical not connected by a carbon to carbon bond with R.
7 . The softgel capsule of claim 3 , wherein said aliphatic sulfonate salt is derived from an ester of an aliphatic dibasic acid having the formula
in which R is an aliphatic carbon chain containing at least one sulphonic group but free from other substituents, and X is hydrogen or an alcohol or phenol radical not connected by a carbon to carbon bond with R, at least one X being such an alcohol or phenol radical and Me is hydrogen or a base.
8 . The softgel capsule of claim 3 , wherein said aliphatic sulfonate salt is derived from an ester of an aliphatic dibasic acid having the formula
in which R is an aliphatic carbon chain containing at least one sulphonic group, but free from other substituents, and X is an alcohol or phenol radical not connected by a carbon to carbon bond with R.
9 . The softgel capsule of claim 3 , wherein said aliphatic sulfonate salt is derived from an ester of an aliphatic dibasic acid having the formula
in which R is an aliphatic carbon chain containing at least one suiphonic group, but free from other substituents, X is an alcohol or phenol radical not connected by a carbon to carbon bond with R, and Me is hydrogen or a base.
10 . The softgel capsule of claim 3 , wherein said aliphatic sulfonate salt is derived from an ester of an aliphatic dibasic acid having the formula
in which R is an aliphatic carbon chain containing at least one sulphonic group and free from mercapto groups and X is an alcohol or phenol radical and Y is a different alcohol or phenol radical.
11 . The softgel capsule of claim 3 , wherein said aliphatic sulfonate salt is derived from an ester of an aliphatic dibasic acid having the formula
MeSO 3 —R in which R is a carbon chain free from mercapto groups, Me is a base, X is an alcohol or phenol radical and Y is a different alcohol or phenol radical.
12 . The softgel capsule of claim 6 , wherein said organic sulfonate salt is sodium docusate.
13 . A softgel capsule having incorporated therein another smaller tablet or smaller capsule wherein said smaller tablet or smaller capsule has solid or encapsulated active ingredients that are not compatible with another solid or encapsulated active in the softgel capsule and wherein said capsule incorporates a drying accelerator.
14 . The capsule of claim 13 wherein said drying accelerator is sodium docusate.
15 . In the process of manufacturing softgel capsules of claim 1 by the rotary die process, the improvement which comprises incorporating an organic sulfonate salt in the capsule shell formulation said organic sulfonate being present in effective amounts to accelerate the drying rate of said capsules.
16 . The use of an organic sulfonate salt to enhance the drying rate of softgel capsules wherein said sulfonate is ester of an aliphatic dibasic acid having the formula
in which R is an aliphatic carbon chain containing at least one sulphonic group, but free from other substituents, and X is an alcohol or phenol radical not connected by a carbon to carbon bond with R.
17 . The softgel capsule product of claim 13 , wherein said product is selected from the group consisting of:
(a) one softgel capsule contains an omega oil and the other solid form incorporated into the softgel capsule containing the omega oil contains a statin;
(b) one softgel capsule contains a non-steroidal antiinflammatory and the other solid form incorporated into the softgel capsule containing the non-steroidal antiinflammatory contains an antihistamine; and
(c) one softgel capsule contains an omega oil and the other solid form incorporated into the softgel capsule containing the omega oil contains a salicylate.
18 . The softgel capsule of claim 17 , wherein said omega oil is an omega-3 oil and the statin is selected from the group consisting of mevastatin, lovastatin, pravastatin, fluvastatin, simvastatin, rosuvastatin, cerivastatin and atorvastatin and derivatives and analogs thereof.
19 . The softgel capsule of claim 17 , wherein said non-steroidal antiinflammatory acid is selected from the group consisting of: ibuprofen, naproxen, benoxaprofen, flurbiprofen, fenoprofen, fenbufen, ketoprofen, indoprofen, pirprofen, carprofen, oxaprozin, pranoprofen, miroprofen, tioxaprofen, suprofen, alminoprofen, tiaprofenic acid, fluprofen, bucloxic acid, indomethacin, sulindac, tolmetin, zomepirac, diclofenac, fenclofenac, alclofenac, ibufenac, isoxepac, furofenac, tiopinac, zidometacin, acemetacin, fentiazac, clidanac, oxpinac, mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid and tolfenamic acid, diflunisal, flufenisal and piroxicam and said antihistamine is selected from the group consisting of: diphenhydramine, loratadine, cetirizine, fexofenadine, hydroxyzine, cyproheptadine, chlorphenamine, clemastine and desloratadine.
20 . The softgel capsule of claim 17 , wherein said salicylate is acetylsalicylic acid.